Femasys announces the first commercial procedure using its FemaSeed intratubal insemination product. “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick. “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court. We are enthusiastic about expanding FemaSeed’s availability and anticipate broader acceptance within the medical community as its distinct benefits become more widely recognized.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FEMY:
- Femasys Reveals Corporate Update and FDA-Cleared Infertility Solution
- Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
- Femasys’ FemaSeed to serve as first-line therapeutic option
- Alabama decision could spur interest in Femasys, says JonesResearch
- Femasys Welcomes New Chief Commercial Officer Mr. Spector
